Tilman Heise1, Gunhild Sommer1. 1. Department for Pediatric Hematology, Oncology and Stem Cell Transplantation, University Hospital Regensburg, Franz-Josef-Strauss Allee 11, 93053 Regensburg, Germany.
Abstract
BACKGROUND: the aberrant overexpression of predominantly nuclear localizing RNA-binding protein (RBP) La contributes to proliferation, mobility, and chemoresistance of cancer cells and tumor growth in mice. METHODS: studies included cancer tissue microarrays (TMAs) analyses, cancer tissue data mining, transforming growth factor β (TGFβ)-induced cancer cell plasticity studies, three dimensional sphere growth, epithelial to mesenchymal transition (EMT) assays, analysis of cancer stem cell (CSC) marker expression, and post-translational modification of cancer-associated La protein. RESULTS: we demonstrated that significant overexpression of RBP La in lung and head and neck cancer tissue correlates with poor overall survival. Furthermore, small interfering RNA-mediated depletion of La reduced proliferation and migration of cancer cells, blocked TGFβ-induced EMT, and diminished both EMT and CSC marker expression. Rescue experiments with La wildtype but not RNA chaperone domain activity-defective La mutant increased the expression of those cancer progression markers, suggesting a critical role of La's RNA chaperone activity in this process. La depletion in cancer cells also significantly decreased sphere growth in the presence of TGFβ. Interestingly, TGFβ treatment induced phosphorylation of La at threonine 389 (pLaT389) only in adherents but not in 3D growing cultures. CONCLUSION: our study suggests that the TGFβ/AKT/pLaT389 signaling pathway regulates cancer cell plasticity.
BACKGROUND: the aberrant overexpression of predominantly nuclear localizing RNA-binding protein (RBP) La contributes to proliferation, mobility, and chemoresistance of cancer cells and tumor growth in mice. METHODS: studies included cancer tissue microarrays (TMAs) analyses, cancer tissue data mining, transforming growth factor β (TGFβ)-induced cancer cell plasticity studies, three dimensional sphere growth, epithelial to mesenchymal transition (EMT) assays, analysis of cancer stem cell (CSC) marker expression, and post-translational modification of cancer-associated La protein. RESULTS: we demonstrated that significant overexpression of RBP La in lung and head and neck cancer tissue correlates with poor overall survival. Furthermore, small interfering RNA-mediated depletion of La reduced proliferation and migration of cancer cells, blocked TGFβ-induced EMT, and diminished both EMT and CSC marker expression. Rescue experiments with La wildtype but not RNA chaperone domain activity-defective La mutant increased the expression of those cancer progression markers, suggesting a critical role of La's RNA chaperone activity in this process. La depletion in cancer cells also significantly decreased sphere growth in the presence of TGFβ. Interestingly, TGFβ treatment induced phosphorylation of La at threonine 389 (pLaT389) only in adherents but not in 3D growing cultures. CONCLUSION: our study suggests that the TGFβ/AKT/pLaT389 signaling pathway regulates cancer cell plasticity.
Entities:
Keywords:
AKT; CSC; EMT; La protein; La/SSB; LaRP3; RBP; RNA-binding protein; TGFβ; cancer stem cells; phosphorylation; plasticity
Authors: G Sommer; J Dittmann; J Kuehnert; K Reumann; P E Schwartz; H Will; B L Coulter; M T Smith; T Heise Journal: Oncogene Date: 2010-09-20 Impact factor: 9.867
Authors: T E Carey; K A Kimmel; D R Schwartz; D E Richter; S R Baker; C J Krause Journal: Otolaryngol Head Neck Surg Date: 1983-10 Impact factor: 3.497
Authors: Letizia Porcelli; Rosa Maria Iacobazzi; Roberta Di Fonte; Simona Serratì; Angelica Intini; Antonio Giovanni Solimando; Oronzo Brunetti; Angela Calabrese; Francesco Leonetti; Amalia Azzariti; Nicola Silvestris Journal: Cancers (Basel) Date: 2019-03-07 Impact factor: 6.639
Authors: Mark Jakob; Kariem Sharaf; Markus Schirmer; Martin Leu; Stefan Küffer; Mattis Bertlich; Friedrich Ihler; Frank Haubner; Martin Canis; Julia Kitz Journal: Strahlenther Onkol Date: 2020-06-25 Impact factor: 3.621